Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,770,281 shares of the medical equipment provider's stock after purchasing an additional 307,109 shares during the quarter. Hsbc Holdings PLC owned 1.23% of Hologic worth $199,723,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter worth approximately $26,000. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Finally, Smithfield Trust Co boosted its position in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Trading Up 2.2 %

HOLX opened at $58.19 on Wednesday. Hologic, Inc. has a 1-year low of $55.89 and a 1-year high of $84.67. The stock has a market capitalization of $13.06 billion, a PE ratio of 18.36, a PEG ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average price of $61.34 and a two-hundred day moving average price of $70.45.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Finally, Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.